FDA admits COVID-19 vaccine killed kids
This fact-check may be outdated. Consider refreshing it to get the most current information.
Executive summary
The FDA’s top vaccine official, Dr. Vinay Prasad, told agency staff in a memo that an internal review “concludes that no fewer than 10 [children’s deaths] are related” to COVID-19 vaccination, citing myocarditis as the likely mechanism; the claim is based on an initial analysis of 96 deaths and has not been published in a peer‑reviewed journal or accompanied by case details [1] [2]. Major news organizations report the FDA has since expanded an inquiry to include adults and that public-health experts and outside reporters say the agency has not released the underlying evidence needed to evaluate the conclusion [3] [4].
1. What the FDA memo actually said — and what it didn’t
The memo, written by Dr. Vinay Prasad, told staff that an internal re‑examination found at least 10 pediatric deaths “related” to COVID-19 vaccination and described myocarditis as the apparent cause in those cases; the review looked at 96 deaths from 2021–2024, according to reporting based on the memo [1] [2]. The memo did not provide ages, medical histories, timelines, manufacturers, or the clinical documentation that led to the attribution, and the FDA’s findings have not been made public or peer‑reviewed [5] [6].
2. How media outlets and public-health bodies have reacted
Reuters, The New York Times, The Washington Post, STAT, NPR, CNN, The Guardian, BMJ and others reported the memo and noted the lack of released data; many outlets emphasize that the agency has not published supporting evidence and experts have urged transparency before accepting such conclusions [1] [4] [7] [2] [8] [9] [10] [11]. HHS and FDA spokespeople have said the review is ongoing and that the FDA is conducting a broader investigation into deaths across age groups [9] [3].
3. Why experts are skeptical — and what they say
Public‑health and clinical experts quoted in reporting described the claim as “extraordinary” without accompanying data and warned that determining causation for deaths temporally linked to vaccination is complex; they note myocarditis risk was identified earlier in younger males but that overall serious vaccine adverse events were rare in previous surveillance [2] [9] [12]. Independent fact‑checkers and journalists stress that the agency presented no case‑level evidence in the memo and that conclusions cannot be independently evaluated until data are released [13] [5].
4. The wider regulatory and political context
Reporting places the memo amid a broader political shift: Robert F. Kennedy Jr., as HHS secretary, has pushed changes to vaccine policy and questioned COVID vaccine safety, and Prasad’s memo frames tougher vaccine oversight as a consequence of the review [10] [7] [14]. Several outlets point out critics view the timing and vagueness of the memo as politically consequential for routine childhood immunization policy debates [10] [6].
5. What the publicly available numbers show (and don’t show)
Articles cite the review’s internal numbers — 96 deaths examined, with 10 judged related to vaccination — but none of the stories include the underlying case reports, adjudication criteria, or peer‑reviewed analysis necessary to confirm causation; the CDC and FDA historically rely on systems such as VAERS for signals but emphasize VAERS reports alone do not prove causation [1] [9] [2]. Reporting also notes that previous CDC data showed more deaths from COVID‑19 itself in children than the figure cited for vaccine‑related deaths, though direct comparisons require careful case‑by‑case analysis not provided in the memo [1].
6. How to evaluate competing claims going forward
The crucial next steps—releasing case‑level data, the methodology for attribution, and independent peer review—are not yet fulfilled, and journalists and experts across outlets call for transparency before changing vaccine policy or public messaging [6] [2] [13]. The FDA has said it will announce regulatory changes “soon,” but reporting stresses that policy should rest on data released for external scrutiny [10] [7].
Limitations and closing note
Available sources do not include the underlying case reports, charts, or adjudication criteria from the FDA’s internal review; therefore I cannot independently confirm the cause‑of‑death attributions the memo asserts [1] [2]. Reporting consistently shows the claim exists in an internal memo and that major outlets and experts demand the data be published for independent assessment [5] [4] [2].